$1.42 $0.00 (0.0%)

04:00 PM EST on 11/20/19

Athersys, Inc. (NASDAQ:ATHX)

CAPS Rating: 1 out of 5

Current Price $1.42 Mkt Cap $222.5M
Open $1.41 P/E Ratio 0.00
Prev. Close $1.42 Div. (Yield) $0.00 (0.0%)
Daily Range $1.41 - $1.48 Volume 652,438
52-Wk Range $1.20 - $2.03 Avg. Daily Vol. 439,678

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

79 Outperform
15 Underperform
 

All-Star Players

5 Outperform
10 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ATHX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Dublin43016 (< 20)
Submitted February 22, 2014

1. Recent regulatory changes to accelerate regenerative medicine use in Japan, will allow faster development of their products. CEO has already made several trips so as to get his ducks in a row.2.Second quarter results on phase II study on… More

SmartAce (99.97)
Submitted October 02, 2018

The most unrealistic thing I've ever seen in a movie is when an entire family sits down to eat breakfast together on a weekday.

NASDAQ:ATHX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ATHX.

Recs

0
Member Avatar jw2net (< 20) Submitted: 2/19/2016 11:33:47 AM : Outperform Start Price: $1.64 NASDAQ:ATHX Score: -75.31

athx

Recs

0
Member Avatar zzlangerhans (99.78) Submitted: 2/3/2016 3:56:25 PM : Underperform Start Price: $1.28 NASDAQ:ATHX Score: +53.63

Nothing new from my last red thumb except an inexplicable price rebound despite a crashing sector, so I'll repost my last pitch.

I just wasted close to an hour trying to translate pages of handwaving from the last Athersys conference call into actionable information. My takeaway: I'm supposed to ignore all the negative developments over the last few years with MultiStem because cytokines. Add this to the company's recent Enjo Kosai activities with various small Japanese pharmas and we have a market cap of 104M, cash of about 40M (inclusive of Healios upfront payment), and a probable inert stem cell soup therapy. Athersys share price is holding up while former darlings StemCells, Caladrius, and Pluristem are going down the toilet but don't expect that to last long as spec biotech remains volatile and new positive catalysts fail to appear during the year.

Recs

0
Member Avatar LifeScientist (32.28) Submitted: 1/11/2016 3:03:33 PM : Underperform Start Price: $1.23 NASDAQ:ATHX Score: +46.92

overstated reporting in annual

Leaderboard

Find the members with the highest scoring picks in ATHX.

Score Leader

zzlangerhans

zzlangerhans (99.78) Score: +255.92

Looks like the momo traders have harpooned Athersys pretty good, and I'm along for the ride for now.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Billdo2211 81.42 12/8/2011 Underperform 3M $2.24 -36.61% +148.10% +184.71 0 Comment
kevrose31 82.05 1/10/2014 Underperform 1Y $4.08 -65.20% +68.90% +134.10 0 Comment
Halffrenzy 26.10 2/28/2014 Underperform 5Y $3.87 -63.31% +66.24% +129.55 0 Comment
MFBurritoSquat 94.30 1/17/2013 Underperform 3M $1.24 +14.42% +110.47% +96.05 0 Comment
MMCapitalMgmt 99.92 4/14/2016 Underperform 5Y $2.49 -42.97% +49.37% +92.34 0 Comment
IdahoInvestor 42.41 10/23/2012 Underperform 5Y $1.06 +33.96% +119.33% +85.37 0 Comment
RafaelStock 99.21 8/1/2016 Underperform 5Y $2.23 -36.32% +43.05% +79.38 0 Comment
zzlangerhans 99.78 2/3/2016 Underperform 1Y $1.28 +11.11% +64.74% +53.63 1 Comment
RunandHide < 20 4/28/2014 Underperform 5Y $1.19 +19.83% +66.91% +47.08 0 Comment
LifeScientist 32.28 1/11/2016 Underperform 3M $1.23 +15.92% +62.84% +46.92 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ATHX.